Killernut referenced an abstract, not the announcement.

But re-reading the announcement, it does leaves things up in the air. It does not state if it's good or bad. Some I suppose could construe it to be bad and some not so bad. 

 "This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention.  The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study.  As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study."

Koo